A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MRAs / mineralocorticoid receptor antagonists

[Related PubMed/MEDLINE]
Total Number of Papers: 162
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MRAs  (>> Co-occurring Abbreviation)
Long Form:   mineralocorticoid receptor antagonists
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A New Role for the Aldosterone/Mineralocorticoid Receptor Pathway in the Development of Mitral Valve Prolapse. ALDO, CT-1, EndMT, MVP, NDF, VECs, VIC
2020 Antihypertensive therapy in patients receiving maintenance hemodialysis: a narrative review of the available clinical-trial evidence. ACEIs, ARBs, BP, CV
2020 Atrial Fibrillation in Primary Aldosteronism. AF, EH, NOAF, PA
2020 Basal Plasma Aldosterone Concentration Predicts Therapeutic Outcomes in Primary Aldosteronism. AVS, hPA, nPA, PA, PAC
2020 Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden. ADL, MDDAS
2020 Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure. HF
2020 Clinical Implications of SARS-Cov2 Interaction with Renin Angiotensin System. ACE2, ARBs
2020 Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial. AF, CIs, HF, HFpEF, HRs, IQR
2020 Mineralocorticoid receptor antagonist use following heart failure hospitalization. HF
10  2020 Mineralocorticoid Receptor Antagonist Use in Heart Failure With Reduced Ejection Fraction and End-Stage Renal Disease Patients on Dialysis: A Literature Review. ESRD, HFrEF
11  2020 Mineralocorticoid Receptor Antagonist Utilization in a Nationally Representative Heart Failure With Reduced Ejection Fraction Outpatient Population: A Cross-Sectional Study. CI, HFrEF
12  2020 Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease. ACEI, ARB, CKD, HF
13  2020 Mineralocorticoid receptor antagonists in heart failure patients with chronic kidney disease: why, when, and how? CHF, CKD, ESKD
14  2020 Mineralocorticoid receptor antagonists lead to increased adenosine bioavailability and modulate contractile cardiac parameters. ADA, ADO, EPL, NT5E, SPI
15  2020 Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in HeartFailure With Reduced Ejection Fraction. CI, HFrEF, HR, SBP
16  2020 Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease. ACE, ARBs, DKD, SGLT2
17  2020 Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials. HF
18  2020 Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. HF, LVEF, RALES, RCTs
19  2020 Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). HFpEF
20  2020 Twenty-year time trends in use of evidence-based heart failure drug therapy in Denmark. ACEIs, ARBs, HF
21  2019 Adherence to ESC guideline-recommended medications over a 36-month follow-up period after hospitalization for heart failure: Results from the EPICAL2 cohort study. ACEI, ARB, BB, ESC, HFrEF, RAS
22  2019 Association between evidence-based medication at discharge and outcomes in patients with heart failure: a systematic review and meta-analysis. EBMs, HF, HFrEF, HRs, RASIs, RRs
23  2019 Blockade of Renin-Angiotensin-Aldosterone System in Elderly Patients with Heart Failure and Chronic Kidney Disease: Results of a Single-Center, Observational Cohort Study. CKD, GFR, HFrEF
24  2019 Building the Foundation for a New Era of Quadruple Therapy in Heart Failure. ACE, ARBs, ARNi, GDMT, HFrEF, SGLT2i
25  2019 Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism. ---
26  2019 Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials. HF, RCTs, SUCRA
27  2019 Effects of Mineralocorticoid Receptor Antagonists on Atrial Fibrillation Occurrence: A Systematic Review, Meta-Analysis, and Meta-Regression to Identify Modifying Factors. AF
28  2019 Effects of mineralocorticoid receptor antagonists on left ventricular diastolic function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. HFpEF, LV, QOL, RCTs
29  2019 Efficacy and safety of mineralocorticoid receptor antagonists with ACEI/ARB treatment for diabetic nephropathy: A meta-analysis. DN, MD
30  2019 Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials. ACEI, ARBs, ARNI, BB, HF, HFrEF
31  2019 Eplerenone in patients with myocardial infarction and "mid-range" ejection fraction: An analysis from the EPHESUS trial. EF, HF, MI
32  2019 Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue? HTN
33  2019 Evaluation of drugs used in chronic heart failure at tertiary care centre: a hospital based study. ACEIs, ARBs, BBs, CHF, NYHA
34  2019 Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection. ---
35  2019 Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate. HFrEF
36  2019 Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. ICD, LVSD, RALES, SCD
37  2019 Impacts of person-centred integrated chronic heart failure and palliative home care on pharmacological heart failure treatment: a substudy of a randomised trial. ACEIs, BBs, CHF, PREFER
38  2019 Medical therapy doses at hospital discharge in patients with existing and de novo heart failure. HFrEF
39  2019 Mineralocorticoid Antagonism and Diabetic Kidney Disease. ACE, ARB, DKD, GLP-1, RAAS, SGLT2, T2D
40  2019 Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. CKD, SGLT2
41  2019 MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT. HF, HFpEF, HFrEF, IPD
42  2019 New Molecules for Treating Resistant Hypertension: a Clinical Perspective. ASIs, BP, CKD, DbetaH, NHE3, NPRA-A, RAS, RH, VIP
43  2019 Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study. CKD, HF, T2D
44  2019 Pharmacological Heart Failure Therapy in Children: Focus on Inotropic Support. ACEIs, ARBs
45  2019 Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. PICP, PIIINP
46  2019 Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy. CSC, SRD
47  2019 Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction. ACEI, ARBs, GLS, LVEF
48  2019 Sacubitril/Valsartan Therapy for 14 Months Induces a Marked Improvement of Global Longitudinal Strain in Patients With Chronic Heart Failure: A Retrospective Cohort Study. ACE, ARBs, CHF, GLS, LVEF, NYHA, RCTs
49  2019 [Antifibrotic renal role of mineralcorticoid receptor antagonists]. CKD, MR
50  2018 A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial. HF
51  2018 A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure. HF, OR
52  2018 A risk score to predict the absence of left ventricular reverse remodeling: Implications for the timing of ICD implantation in primary prevention. ACE, ARBs, HF, HFrEF, ICD, LVEDDI, LVEF, LVRR
53  2018 Association is not causation: treatment effects cannot be estimated from observational data in heart failure. HF, RCTs
54  2018 Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure. AHF, ALARM-HF, HR
55  2018 Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: ResultsFrom BIOSTAT-CHF. ACE, ARBs
56  2018 Drug therapies in chronic heart failure: a focus on reduced ejection fraction. CKD, HF
57  2018 Efficacy of mineralocorticoid receptor antagonists in postmyocardial infarction patients with or without left ventricular dysfunction: A meta-analysis of randomized controlled trials. CI, HF, LVD, LVEF, MI, RCTs, RR
58  2018 EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) study: study protocol for a randomized controlled trial. ECDs, IRI, KT
59  2018 Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. HF, HFrEF, NYHA
60  2018 How are patients with heart failure treated in primary care?
. ACEIs, ARBs, BBs, GAI-3, GPs, HFpEF, HFrEF
61  2018 Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. CKD
62  2018 Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. ACEIs, ARBs, ARNI, BBs, CrI, HFrEF, IVA, NMA
63  2018 Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction. adjHR, STEMI
64  2018 Mineralocorticoid receptor antagonists (MRAs): more attention required (to prescription)! ---
65  2018 Mineralocorticoid receptor antagonists for heart failure: a real-life observational study. ---
66  2018 Mineralocorticoid receptor antagonists in kidney transplantation: time to consider? CKD, CV, GFR, KT, RCTs
67  2018 Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. ACE, ARBs, HFrEF, HR
68  2018 Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism. PA
69  2018 Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity. pre, TNX
70  2018 Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. AF, HF
71  2018 The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction. HF, HFrEF
72  2018 The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis. CHF, CI, eGFR, MD, RR, TEAEs, UACR
73  2017 Adherence to the guidelines on the management of systolic heart failure in ambulatory care in Poland. Data from the international QUALIFY survey. ACEIs, ARBs, HF
74  2017 Evidence for the use of mineralocorticoid receptor antagonists in the treatment of coronary artery disease and post-angioplasty restenosis. CAD
75  2017 Future drug discovery in renin-angiotensin-aldosterone system intervention. RAASis
76  2017 Hyperkalemia in both surgically and medically treated patients with primary aldosteronism. PA
77  2017 Impact of Hyperkalemia and Worsening Renal Function on the Use of Renin Angiotensin Aldosterone System Inhibitors in Chronic Heart Failure With Reduced Ejection Fraction. HF
78  2017 Influence of antihypertensive drugs on aortic and coronary effects of Ang-(1-7) in pressure-overloaded rats. AB, ACEIs
79  2017 Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists. RHTN
80  2017 Mineralocorticoid antagonists in chronic kidney disease. CKD
81  2017 Mineralocorticoid Antagonists in ESRD: An Overview of Clinical Trial Evidence. ACEIs, ARBs, CHF, LV
82  2017 Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. HFrEF
83  2017 Mineralocorticoid receptor antagonists in elderly patients with heart failure: a systematic review and meta-analysis. HEFPEF, HEFREF, HF, RCTs
84  2017 Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. ACEI, HF, HFrEF
85  2017 New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations. HF, HFpEF
86  2017 Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. DKD
87  2017 Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism. eGFR, PA
88  2017 Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. ACEIs, ARBs, BBs, CI, HF, HFrEF, HR
89  2017 Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. HFrEF
90  2017 Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach? HFpEF, HFrEF
91  2017 Understanding the economic burden of heart failure in China: impact on disease management and resource utilization. ACEI, ARB, BB, CHIRA, HF
92  2016 Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. CIs, eGFR, HFrEF, HRs, SBP
93  2016 Barriers to Adoption of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure: A Mixed-Methods Study. ---
94  2016 Clinical Outcomes in Dialysis Patients: Prospects for Improvement with Aldosterone Receptor Antagonists. CKD, ESRD
95  2016 Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis. BP, CI, DBP, DM, RAS, SBP
96  2016 Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis. CIs, CKD, LVM, LVMI, MACEs, MD, RRs, SMD
97  2016 Efficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysis. DM, HF
98  2016 General practitioners' adherence to chronic heart failure guidelines regarding medication: the GP-HF study. GPs, HF
99  2016 Global cardiovascular protection in chronic kidney disease. CKD, CVD
100  2016 Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. HFpEF, LVEF